Navigation Links
Successful Field-Trial Remediation of 1,2-DCA and VC Contaminated Groundwater in Northern Italy
Date:6/3/2009

Gruppo TRS Selects Adventus EHC® Enhanced Natural Attenuation Biotechnology as Demonstrably Superior to Alternatives

New York, NY (Vocus) June 3, 2009 -- The Adventus Group, an international remediation biotechnology enterprise for treatment of contaminated soil, sediment and groundwater environments, is proud to announce that laboratory and field tests recently conducted in Italy resulted in its patented EHC® In Situ Chemical Reduction (ISCR) biotechnology being selected over RegenOx® (Regenesis) In Situ Chemical Oxidation (ISCO) for its ability to meet vendor claims and client expectations for an effective, cost-efficient remedial strategy. The environmental engineering firm of Gruppo TRS conducted extensive testing, and presented their findings at the BOSICON 2009 International Conference on Remediation of Polluted Sites, held May 13-15 in Rome, Italy.

ABSTRACT

The presentation described rigorous laboratory and field tests conducted to select and optimize an in situ remedial design for a large, complex site located inside an operating petrochemical plant in Northern Italy. The subsurface e
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3 4

Related biology technology :

1. Orthocrat Announces Successful Implementation of TraumaCad at UPMC Mercy
2. Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB
3. Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
4. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
5. VeraSun Energy Selects Valero as Successful Bidder for Seven Facilities
6. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
7. EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology
8. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period
9. DiFUSION Technologies Completes Successful Testing of Antimicrobial Spinal Implant
10. WaferGens SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program
11. GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Successful Field-Trial Remediation of 1,2-DCA and VC Contaminated Groundwater in Northern Italy
Successful Field-Trial Remediation of 1,2-DCA and VC Contaminated Groundwater in Northern Italy
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2EUCODIS Bioscience Appoints Thomas Fischer as New CEO 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3
Other Biology Technology:Covaris Installed Instrument Base Reaches 500 Units 2Shasta Regional Medical Center Awarded Full Accreditation from the Joint Commission 2Shasta Regional Medical Center Awarded Full Accreditation from the Joint Commission 3Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 2Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 3Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 4Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 5Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 6Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 7Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 8Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 9Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 10Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 11Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 12Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 13Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 14Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 15Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 16Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 17